Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 126Carboplatin 108Pemetrexed 76Paclitaxel 76Cisplatin 73Nivolumab 56Docetaxel 53Erlotinib Hydrochloride 50Gemcitabine 49Radiotherapy 48Bevacizumab 32osimertinib 31Cetuximab 29atezolizumab 25Cyclophosphamide 25durvalumab 24130-nm albumin-bound paclitaxel 22Oxaliplatin 19Fluorouracil 18Taxes 17Radiosurgery 17fludarabine 16Magnetic Resonance Spectroscopy 16Gefitinib 16Ipilimumab 15Vinorelbine 14Leucovorin 14Albumin-Bound Paclitaxel 14Vorinostat 13Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Non-Small-Cell Lung × mocetinostat × Clear all
NCT00511576 2015-01-08

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Mirati Therapeutics Inc.

Phase 1 Terminated
54 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡